CN105748929A - Folium-artemisiae-argyi-containing traditional Chinese medicine composition for treating lung cancer and preparation method thereof - Google Patents

Folium-artemisiae-argyi-containing traditional Chinese medicine composition for treating lung cancer and preparation method thereof Download PDF

Info

Publication number
CN105748929A
CN105748929A CN201610196388.6A CN201610196388A CN105748929A CN 105748929 A CN105748929 A CN 105748929A CN 201610196388 A CN201610196388 A CN 201610196388A CN 105748929 A CN105748929 A CN 105748929A
Authority
CN
China
Prior art keywords
parts
radix
chinese medicine
medicine composition
herba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610196388.6A
Other languages
Chinese (zh)
Inventor
王飞
王一飞
王璐
利奕成
马婧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Jinan Biomedicine Research and Development Base Co Ltd
Original Assignee
Guangzhou Jinan Biomedicine Research and Development Base Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Jinan Biomedicine Research and Development Base Co Ltd filed Critical Guangzhou Jinan Biomedicine Research and Development Base Co Ltd
Priority to CN201610196388.6A priority Critical patent/CN105748929A/en
Publication of CN105748929A publication Critical patent/CN105748929A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/342—Adenophora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/78—Saururaceae (Lizard's-tail family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to the technical field of traditional Chinese medicine and discloses a folium-artemisiae-argyi-containing traditional Chinese medicine composition for treating lung cancer and a preparation method thereof.The traditional Chinese medicine composition comprises, by weight, 5-25 parts of folium artemisiae argyi, 6-25 parts of rhizoma corydalis, 8-20 parts of roots of celastrus kusanm hayata, 5-15 parts of radix adenophorae, 5-15 parts of pepperweed seeds, 9-15 parts of Indian mockstrawberrg herbs, 6-12 parts of flabellate hemipilia herbs, 3-9 parts of radix astragali, 3-9 parts of rhizoma atractylodis macrocephalae, 6-12 parts of Chinese magnoliavine fruits, 3-10 parts of herba houttuyniae, 3-9 parts of angelica sinensis and 1-10 parts of liquorice roots.The traditional Chinese medicine composition is simple in component, reasonable in compatibility, small in toxic and side effect and convenient to use, has the effects of relieving pain, strengthening body resistance and eliminating toxic materials and can effectively relieve symptoms of lung cancer.

Description

A kind of Chinese medicine composition for the treatment of pulmonary carcinoma containing Folium Artemisiae Argyi and preparation method thereof
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of Chinese medicine composition for the treatment of pulmonary carcinoma containing Folium Artemisiae Argyi and preparation method thereof.
Background technology
Pulmonary carcinoma is modal lung primary malignant tumor, and most pulmonary carcinoma originate from bronchial mucosa epithelium, therefore also known as lung bronchogenic carcinoma.At present Pulmonary carcinoma is the first place of the whole world cancer cause of the death, nineteen ninety-five the whole world have 600,000 people to die from pulmonary carcinoma, and annual number is all rising.Women suffers from lung The incidence rate of cancer especially has the trend of rising.Primary disease is many fell ill more than 40 years old, and age of onset peak is between 60～79 years old.Men and women's prevalence is 2.3: 1. The morbidity of pulmonary carcinoma is all had an impact by race, family members' history with smoking.
The cause of disease of pulmonary carcinoma is the clearest and the most definite, great mass of data show the risk factor of pulmonary carcinoma comprise smoking (including second hand smoking), asbestos, radon, Arsenic, ionizing radiation, halogen alkenes, polycyclic aromatic, nickel etc..The patients with lung cancer of about 80% has been late period when making a definite diagnosis, and has surpassed Having got over the scope of radical excision, thus cure rate is the highest, NSCLC5 annual survival rate only has 10%-15%.
The treatment means of pulmonary carcinoma has operation, radiotherapy, Drug therapy and the Comprehensive Treatment of above-mentioned therapy at present.In radiotherapy, chemotherapy Can suppress medulla hematopoietic system, mainly leukocyte and hematoblastic decline, associating Chinese medicine and immunotherapeutic effects are good.Pain relieving does not typically carry Advocating doctor trained in Western medicine pain relieving, its effect is to be realized by anesthesia nerve mostly, cures the symptoms, not the disease, and some Western medicine such as dolantin is the most addicted and produces drug resistance, Treatment by Chinese herbs is taked in suggestion, is reached the purpose of pain relieving by the copy function cutting off cancerous cell.Chinese medicine is little because of lasting medicine, side effect, becomes trouble The first-selection of person, alleviating that patient is painful, extend its life, improve its quality of life for the purpose of.
Chinese invention patent application 201310531426.5 relates to a kind of medicine treating pulmonary carcinoma, and this Chinese medicine preparation includes following Chinese crude drug: Radix Ginseng, spirit Sesame, Radix Codonopsis, Fructus Schisandrae Chinensis, Spica Prunellae, Herba Hedyotidis Diffusae, Herba Houttuyniae, Fructus Bruceae, Semen Vaccariae, the Radix Astragali, Fructus Lycii, Fructus Ligustri Lucidi Son, Rhizoma Dioscoreae, Semen Euryales, the Rhizoma Atractylodis Macrocephalae, Radix Glehniae, Carapax Trionycis, Rhizoma Polygonati Odorati, Herba Dendrobii, Radix Sophorae Tonkinensis, Radix Curcumae, Radix Peucedani, Cortex Lycii, Fructus Trichosanthis, Concretio Silicea Bambusae, Radix Paeoniae Rubra, Radix Angelicae Sinensis, Pseudobulbus Cremastrae Seu Pleiones, Caulis Spatholobi, Radix Platycodonis, Rhizoma Curcumae, Rhizoma Chuanxiong and Radix Glycyrrhizae.Treatment pulmonary carcinoma there is is certain curative effect, but There is the problems such as uncertain therapeutic efficacy is cut, efficiency is low, medical material the most not easy exploiting.
Summary of the invention
It is an object of the invention to overcome weak point of the prior art, it is provided that in the treatment pulmonary carcinoma that a kind of with strong points, instant effect, side effect are low Drug composition.
For realizing the purpose of the present invention, technical solution of the present invention is as follows:
The Chinese medicine composition for the treatment of pulmonary carcinoma of the present invention includes the Chinese crude drug of following parts by weight:
Folium Artemisiae Argyi 5-25 part, Rhizoma Corydalis 6-25 part, roundleaf Radix Celastri Orbiculati 8-20 part, Radix Adenophorae (Radix Glehniae) 5-15 part, Semen Lepidii (Semen Descurainiae) 5-15 part, Herba Duchesneae Indicae 9-15 part, Herba Hemipiliae Flabellatae 6-12 part, Radix Astragali 3-9 part, Rhizoma Atractylodis Macrocephalae 3-9 part, Fructus Schisandrae Chinensis 6-12 part, Herba Houttuyniae 3-10 part, Radix Angelicae Sinensis 3-9 part and Radix Glycyrrhizae 1-10 Part.
Preferably, the Chinese medicine composition for the treatment of pulmonary carcinoma of the present invention includes the Chinese crude drug of following parts by weight: Folium Artemisiae Argyi 5 parts, Rhizoma Corydalis 6 parts, Roundleaf Radix Celastri Orbiculati 8 parts, Radix Adenophorae (Radix Glehniae) 5 parts, Semen Lepidii (Semen Descurainiae) 5 parts, Herba Duchesneae Indicae 9 parts, Herba Hemipiliae Flabellatae 6 parts, the Radix Astragali 3 parts, the Rhizoma Atractylodis Macrocephalae 3 parts, Fructus Schisandrae Chinensis 6 parts, Herba Houttuyniae 3 parts, Radix Angelicae Sinensis 3 parts and 1 part of Radix Glycyrrhizae.
It is further preferred that the Chinese medicine composition for the treatment of pulmonary carcinoma of the present invention includes the Chinese crude drug of following parts by weight: Folium Artemisiae Argyi 25 parts, Rhizoma Corydalis 25 parts of rope, roundleaf Radix Celastri Orbiculati 20 parts, Radix Adenophorae (Radix Glehniae) 15 parts, Semen Lepidii (Semen Descurainiae) 15 parts, Herba Duchesneae Indicae 15 parts, Herba Hemipiliae Flabellatae 12 parts, the Radix Astragali 9 parts, white Art 9 parts, Fructus Schisandrae Chinensis 12 parts, Herba Houttuyniae 10 parts, Radix Angelicae Sinensis 9 parts and 10 parts of Radix Glycyrrhizae.
It is further preferred that the Chinese medicine composition for the treatment of pulmonary carcinoma of the present invention includes the Chinese crude drug of following parts by weight: Folium Artemisiae Argyi 15 parts, prolong Rhizoma Corydalis 15 parts, roundleaf Radix Celastri Orbiculati 14 parts, Radix Adenophorae (Radix Glehniae) 10 parts, Semen Lepidii (Semen Descurainiae) 10 parts, Herba Duchesneae Indicae 12 parts, Herba Hemipiliae Flabellatae 9 parts, the Radix Astragali 6 parts, The Rhizoma Atractylodis Macrocephalae 6 parts, Fructus Schisandrae Chinensis 9 parts, Herba Houttuyniae 6 parts, Radix Angelicae Sinensis 6 parts and 5 parts of Radix Glycyrrhizae.
The preparation method that above-mentioned prescription makes finished product Chinese medicine preparation is comprised the following steps:
Step 1, weigh each taste raw medicinal material in proportion；
Step 2, by Folium Artemisiae Argyi, Rhizoma Corydalis, roundleaf Radix Celastri Orbiculati, Radix Adenophorae (Radix Glehniae), Semen Lepidii (Semen Descurainiae), Herba Duchesneae Indicae, Herba Hemipiliae Flabellatae, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Fructus Schisandrae Chinensis, Herba Houttuyniae, Radix Angelicae Sinensis and Radix Glycyrrhizae decontamination respectively, cleans, dries, be ground into coarse powder；
Step 3, the coarse powder of step 2 gained is mixed, add the purified water of 5-12 times of medical material weight, decoct 2-3 time, each 2-5 hour, mistake Filter, merging filtrate, when being condensed into 55 DEG C-65 DEG C, relative density is the water extracting liquid of 1.15-1.20；
Step 4, toward the water extracting liquid of step 3 gained adds the 50-80% ethanol of 4-8 times of medical material weight, in 5-10 DEG C of cold preservation 20-48 hour, Decompression distillation, removes ethanol, and it is the Chinese medical concrete of 1.15-1.20 that filtrate is concentrated into relative density under 55 DEG C of-65 DEG C of environment；
Step 5, Chinese medical concrete step 4 obtained dry, pulverize, and cross 100-200 mesh sieve, obtain traditional Chinese medicine fine powder, in described traditional Chinese medicine fine powder Add adjuvant and make finished product Chinese medicine preparation.
Further, described Chinese medicine preparation is capsule, tablet, powder, granule, pill or decoction.
The source of Chinese crude drug, nature and flavor used by the prescription of Chinese medicine composition of the present invention, return through and effect:
Folium Artemisiae Argyi: this product is the dried leaves of feverfew Chinese mugwort.Acrid in the mouth, hardship, warm in nature；Return liver,spleen,kidney warp；Dispersing cold for relieving pain, warming the meridian for stopping bleeding.
Rhizoma Corydalis: this product is the dry tuber of papaveraceae plant corydalis.Acrid in the mouth, hardship, warm in nature；Return liver, spleen channel；Invigorate blood circulation, promoting the circulation of QI, pain relieving.
Roundleaf Radix Celastri Orbiculati: this product is the root of Celastraceae plant roundleaf Celastrus orbiculatus Thunb..Taste is micro-sweet, and property is put down；Return lung, liver, spleen channel；Moistening lung and nourishing throat, work Blood detoxifies.
Radix Adenophorae (Radix Glehniae): this product is campanulaceae Lady bell plant four leaf sand, Folium Pruni Radix Adenophorae (Radix Glehniae) or its congener, is used as medicine with root.Sweet in the mouth, cool in nature；Return lung, stomach Warp；Clearing away heat and nourishing YIN, nourishing the lung to arrest cough.
Semen Lepidii (Semen Descurainiae): this product is the dry mature seed of crucifer Lepidium sativum L. or descurainia sophia (l.) webb ex prantl.Acrid in the mouth, hardship, property Great Cold；Return lung, bladder warp； Eliminating pathogen from the lung for relieving asthma, line water detumescence.
Herba Duchesneae Indicae: this product is Rosaceae Herba Duchesneae Indicae platymiscium Herba Duchesneae Indicae, with all herbal medicine.Sweet in the mouth, hardship, cold in nature；Return lung, liver, large intestine channel；Heat clearing away, cool Blood, detumescence, removing toxic substances.
Herba Hemipiliae Flabellatae: this product is the Herb that orchid fan words beak is blue.Sweet in the mouth, micro-hardship, property is put down；Return lung meridian；Nourishing YIN and moistening the lung, qi-restoratives stop blooding.
The Radix Astragali: this product is the dry root of leguminous plant Radix Astagali or Radix Astragali.Sweet in the mouth, warm in nature；GUIXIN, lung, spleen, kidney channel；Invigorating QI to consolidate the body surface resistance, Diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.
The Rhizoma Atractylodis Macrocephalae: this product is the dry rhizome of the feverfew Rhizoma Atractylodis Macrocephalae.Bitter in the mouth, sweet, warm in nature；Return spleen, stomach warp；Invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, Antiabortive.
Fructus Schisandrae Chinensis: this product is the dry mature fruit of magnoliaceae schisandra or schisandra chinensis.Sour in the mouth, sweet, warm in nature；Return lung, the heart, kidney channel； Restrain astringent or styptic treatment for spontaneous sweating, supplementing QI for promoting the production of body fluid, kidney calming.
Herba Houttuyniae: this product is the dry aerial parts of saururaceae plant houttuynia cordata.Acrid in the mouth, cold nature；Return lung meridian；Heat-clearing and toxic substances removing, eliminating carbuncle evacuation of pus, Inducing diuresis for treating stranguria syndrome.
Radix Angelicae Sinensis: this product is the dry root of umbelliferae angelica.Sweet in the mouth, pungent, warm in nature；Return liver, the heart, spleen channel；Replenishing and activating blood, menstruction regulating and pain relieving, Loosening bowel to relieve constipation.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L..Sweet in the mouth, property is put down；GUIXIN, lung, spleen, stomach warp；Mend Spleen QI invigorating, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The prescription compatibility of Chinese medicine composition of the present invention is analyzed:
Chinese prescription of the present invention is according to the traditional Chinese medical science dialectical cognition to pulmonary carcinoma, it then follows the compatibility theory of Chinese medicine, in order to make facilitate easy-to-use and stable curative effect Preparation, enhances the usage amount of medical material.This prescription is with Folium Artemisiae Argyi, Rhizoma Corydalis, roundleaf Radix Celastri Orbiculati as monarch drug, promoting the circulation of QI pain relieving, promoting blood circulation and detoxication；With Radix Adenophorae (Radix Glehniae), Semen Lepidii (Semen Descurainiae), Herba Duchesneae Indicae, Herba Hemipiliae Flabellatae are ministerial drug, nourishing YIN and moistening the lung, line water detumescence；With the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Fructus Schisandrae Chinensis, Herba Houttuyniae, Radix Angelicae Sinensis For adjuvant drug, menstruction regulating and pain relieving, invigorating QI to consolidate the body surface resistance；With Radix Glycyrrhizae for making medicine, the coordinating the actions of various ingredients in a prescription property of medicine, all medicines coordinate, complement each other, and synergism plays profit altogether The effects such as gas pain relieving, eliminating pathogen from the lung for relieving asthma, have the most significant curative effect to pulmonary carcinoma.
Compared with prior art, beneficial effect of the present invention is summarized as follows:
The Chinese medicine composition that the present invention provides has the effects such as pain relieving, lung moistening, promoting the circulation of QI, removing toxic substances；Zoopery shows, Chinese medicine composition pair of the present invention Antitumor drug more existing than market has considerably better antitumor action, can significantly inhibit losing weight of lung cancer in mice, increases the food of lung cancer in mice It is intended to, reduces the weight of tumor, and dramatically increase the tumour inhibiting rate of pulmonary carcinoma.Additionally, Chinese medicine composition of the present invention treatment pulmonary carcinoma in terms of have instant effect, The advantages such as toxic and side effects is little, and preparation technology is simple and easy to do, preparation efficacy stability, application easy to spread.
Detailed description of the invention
Below will by specific embodiment, the present invention is described further, it will be understood by those skilled in the art that the present invention in addition to following example also Other similar changing can be made and obtain similar result without deviating from present disclosure and scope.
Embodiment 1
The embodiment of the present invention 1 Chinese medicine composition includes the Chinese crude drug of following parts by weight:
Folium Artemisiae Argyi 5 parts, Rhizoma Corydalis 6 parts, roundleaf Radix Celastri Orbiculati 8 parts, Radix Adenophorae (Radix Glehniae) 5 parts, Semen Lepidii (Semen Descurainiae) 5 parts, Herba Duchesneae Indicae 9 parts, Herba Hemipiliae Flabellatae 6 parts, The Radix Astragali 3 parts, the Rhizoma Atractylodis Macrocephalae 3 parts, Fructus Schisandrae Chinensis 6 parts, Herba Houttuyniae 3 parts, Radix Angelicae Sinensis 3 parts and 1 part of Radix Glycyrrhizae；
Preparation method is as follows:
1, each taste raw medicinal material is weighed in proportion；
2, Folium Artemisiae Argyi, Rhizoma Corydalis, roundleaf Radix Celastri Orbiculati, Radix Adenophorae (Radix Glehniae), Semen Lepidii (Semen Descurainiae), Herba Duchesneae Indicae, Herba Hemipiliae Flabellatae, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Fructus Schisandrae Chinensis, fish raw meat Grass, Radix Angelicae Sinensis and Radix Glycyrrhizae decontamination respectively, cleans, dries, be ground into coarse powder；
3, the coarse powder of step 2 gained is mixed, add the purified water of 5 times of medical material weight, decoct 2 times, each 3 hours, filter, merge filter Liquid, when being condensed into 55 DEG C, relative density is the water extracting liquid of 1.15；
4, toward 50% ethanol of 4 times of medical material weight of addition in the water extracting liquid of step 3 gained, in 5 DEG C of cold preservations 20 hours, decompression distillation, remove Going ethanol, filtrate to be concentrated into relative density under 55 DEG C of environment is the Chinese medical concrete of 1.15；
5, the Chinese medical concrete that step 4 obtains be dry, pulverize, cross 150 mesh sieves, obtain traditional Chinese medicine fine powder, in described traditional Chinese medicine fine powder, add adjuvant Make granule.
Embodiment 2
The embodiment of the present invention 2 Chinese medicine composition includes the Chinese crude drug of following parts by weight:
Folium Artemisiae Argyi 25 parts, Rhizoma Corydalis 25 parts, roundleaf Radix Celastri Orbiculati 20 parts, Radix Adenophorae (Radix Glehniae) 15 parts, Semen Lepidii (Semen Descurainiae) 15 parts, Herba Duchesneae Indicae 15 parts, Herba Hemipiliae Flabellatae 12 parts, the Radix Astragali 9 parts, the Rhizoma Atractylodis Macrocephalae 9 parts, Fructus Schisandrae Chinensis 12 parts, Herba Houttuyniae 10 parts, Radix Angelicae Sinensis 9 parts and 10 parts of Radix Glycyrrhizae；
Preparation method is with embodiment 1.
Embodiment 3
The embodiment of the present invention 3 Chinese medicine composition includes the Chinese crude drug of following parts by weight:
Folium Artemisiae Argyi 15 parts, Rhizoma Corydalis 15 parts, roundleaf Radix Celastri Orbiculati 14 parts, Radix Adenophorae (Radix Glehniae) 10 parts, Semen Lepidii (Semen Descurainiae) 10 parts, Herba Duchesneae Indicae 12 parts, Herba Hemipiliae Flabellatae 9 parts, the Radix Astragali 6 parts, the Rhizoma Atractylodis Macrocephalae 6 parts, Fructus Schisandrae Chinensis 9 parts, Herba Houttuyniae 6 parts, Radix Angelicae Sinensis 6 parts and 5 parts of Radix Glycyrrhizae；
Preparation method is with embodiment 1.
Embodiment 4
The embodiment of the present invention 4 Chinese medicine composition includes the Chinese crude drug of following weight portion:
Folium Artemisiae Argyi 23 parts, Rhizoma Corydalis 20 parts, roundleaf Radix Celastri Orbiculati 20 parts, Radix Adenophorae (Radix Glehniae) 12 parts, Semen Lepidii (Semen Descurainiae) 12 parts, Herba Duchesneae Indicae 11 parts, Herba Hemipiliae Flabellatae 10 parts, the Radix Astragali 9 parts, the Rhizoma Atractylodis Macrocephalae 7 parts, Fructus Schisandrae Chinensis 7 parts, Herba Houttuyniae 5 parts, Radix Angelicae Sinensis 5 parts and 5 parts of Radix Glycyrrhizae；
Preparation method is with embodiment 1.
Chinese medicine composition pharmacodynamic study of the present invention:
The Chinese medicine composition of the present invention impact on mice lung cancer
1, experimental technique
Choose 72 A549 lung cancer model BalB/CA-nu nude mouses and 12 normal BalB/CA-nu nude mouses (are purchased from Beijing Boyto far to create Thing Science and Technology Ltd.；Mus 6-8 in age week；Body weight is 15-30g), male and female half and half, female mice is all without pregnant.72 model mices are divided equally at random It is 6 groups, respectively model group, positive controls, test A, B, C, D group, often group 12；Remaining 12 normal BalB/CA-nu Nude mouse is set to Normal group.The administering mode of each group nude mouse is: Normal group and model group gavage are to isopyknic normal saline, positive To cancer plain film, (Shiyiting Pharmaceutical Factory, Harbin pharmaceutical Industry Group produces matched group gavage；Traditional Chinese medicines quasi-word Z20083240) solution prepared, dosage is 80mg/Kg, The solution of the Chinese medicine composition preparation that test A, B, C, D group gavage respectively prepares to embodiment of the present invention 1-4, dosage is 60mg/Kg, Each group nude mouse gavage every day 2 times, successive administration 1 month.After off-test, weighing each group of nude mouse, the body weight calculating nude mouse becomes Change, then put to death nude mouse, peel off the tumor body of nude mouse and weigh, calculate inhibition rate of tumor growth.Inhibition rate of tumor growth (%)=(model Organize average tumor weight-treatment group average tumor weight)/model group average tumor weight × 100%.
Statistical procedures test data all uses mean ± standard deviation to represent, group difference significance t inspection is compared, and P ＜ 0.05 is for there being significance Difference.SPSS19.0 statistical software is used to carry out data process.
2, experimental result: shown in see table.
Weight gain and the tumor weight of the nude mouse of each test group of table 1 compare
Group Quantity Weight gain (g) Tumor weight (g)
Normal group 12 4.32±0.57 -
Model group 12 -3.60±0.49### 0.89±0.20
Positive controls 12 5.29±0.62*** 0.47±0.12**
Test A group 12 6.38±0.59*** 0.40±0.10**
Test B group 12 6.35±0.61*** 0.43±0.14**
Test C group 12 6.60±0.55***△ 0.37±0.11***
Test D group 12 6.41±0.60*** 0.45±0.13**
Note: compare with Normal group,###P ＜ 0.001；Compare with model group,**P ＜ 0.01,***P ＜ 0.001；Right with the positive Compare according to group,△P ＜ 0.05.
The impact of the tumor growth rate of table 2 each test group nude mouse
Group Quantity Tumour inhibiting rate (%)
Normal group 12 -
Model group 12 0
Positive controls 12 42.19±8.57
Test A group 12 65.36±11.40△
Test B group 12 60.20±10.22△
Test C group 12 70.25±12.31△△
Test D group 12 64.89±10.18△
Note: compare with positive controls,△P ＜ 0.05,△△P ＜ 0.01.
3, conclusion
On the impact that pulmonary carcinoma nude mouse tumor grows, the present invention judges that Chinese medicine composition of the present invention is controlled by research embodiment 1-4 gained Chinese medicine composition Treat the effect of pulmonary carcinoma.A549 human lung adenocarcinoma model is widely used a kind of modeling method in lung cancer animal experiment, has existence adaptive strong, becomes tumor The advantage that rate is high.From Tables 1 and 2 result, Chinese medicine composition of the present invention can significantly inhibit losing weight of lung cancer in mice, improve lung cancer in mice Appetite, and the weight of tumor can be significantly reduced, dramatically increase the suppression ratio of tumor, wherein the effect with test C group is preferable.Chinese medicine of the present invention Compositions is better than the tumour inhibiting rate of positive drug cancer plain film to the tumour inhibiting rate of pulmonary carcinoma.Result above shows, the treatment of pulmonary carcinoma is imitated by Chinese medicine composition of the present invention Fruit is better than positive drug, and has certain safety, can be used for treating pulmonary carcinoma.
Below it is only the preferred embodiment of the present invention, it is noted that above-mentioned preferred implementation is not construed as limitation of the present invention, this Bright protection domain should be as the criterion with claim limited range.For those skilled in the art, without departing from the present invention Spirit and scope in, it is also possible to making some improvements and modifications, these improvements and modifications also should be regarded as protection scope of the present invention.

Claims (7)

1. the Chinese medicine composition for the treatment of pulmonary carcinoma containing Folium Artemisiae Argyi, it is characterised in that described Chinese medicine composition includes the Chinese crude drug of following parts by weight:
Folium Artemisiae Argyi 5-25 part, Rhizoma Corydalis 6-25 part, roundleaf Radix Celastri Orbiculati 8-20 part, Radix Adenophorae (Radix Glehniae) 5-15 part, Semen Lepidii (Semen Descurainiae) 5-15 part, Herba Duchesneae Indicae 9-15 part, Herba Hemipiliae Flabellatae 6-12 part, Radix Astragali 3-9 part, Rhizoma Atractylodis Macrocephalae 3-9 part, Fructus Schisandrae Chinensis 6-12 part, Herba Houttuyniae 3-10 part, Radix Angelicae Sinensis 3-9 part and Radix Glycyrrhizae 1-10 Part.
The Chinese medicine composition for the treatment of pulmonary carcinoma the most according to claim 1, it is characterised in that described Chinese medicine composition includes following parts by weight Chinese crude drug:
Folium Artemisiae Argyi 5 parts, Rhizoma Corydalis 6 parts, roundleaf Radix Celastri Orbiculati 8 parts, Radix Adenophorae (Radix Glehniae) 5 parts, Semen Lepidii (Semen Descurainiae) 5 parts, Herba Duchesneae Indicae 9 parts, Herba Hemipiliae Flabellatae 6 parts, The Radix Astragali 3 parts, the Rhizoma Atractylodis Macrocephalae 3 parts, Fructus Schisandrae Chinensis 6 parts, Herba Houttuyniae 3 parts, Radix Angelicae Sinensis 3 parts and 1 part of Radix Glycyrrhizae.
The Chinese medicine composition for the treatment of pulmonary carcinoma the most according to claim 1, it is characterised in that described Chinese medicine composition includes following parts by weight Chinese crude drug:
Folium Artemisiae Argyi 25 parts, Rhizoma Corydalis 25 parts, roundleaf Radix Celastri Orbiculati 20 parts, Radix Adenophorae (Radix Glehniae) 15 parts, Semen Lepidii (Semen Descurainiae) 15 parts, Herba Duchesneae Indicae 15 parts, Herba Hemipiliae Flabellatae 12 parts, the Radix Astragali 9 parts, the Rhizoma Atractylodis Macrocephalae 9 parts, Fructus Schisandrae Chinensis 12 parts, Herba Houttuyniae 10 parts, Radix Angelicae Sinensis 9 parts and 10 parts of Radix Glycyrrhizae.
The Chinese medicine composition for the treatment of pulmonary carcinoma the most according to claim 1, it is characterised in that described Chinese medicine composition includes following parts by weight Chinese crude drug:
Folium Artemisiae Argyi 15 parts, Rhizoma Corydalis 15 parts, roundleaf Radix Celastri Orbiculati 14 parts, Radix Adenophorae (Radix Glehniae) 10 parts, Semen Lepidii (Semen Descurainiae) 10 parts, Herba Duchesneae Indicae 12 parts, Herba Hemipiliae Flabellatae 9 parts, the Radix Astragali 6 parts, the Rhizoma Atractylodis Macrocephalae 6 parts, Fructus Schisandrae Chinensis 9 parts, Herba Houttuyniae 6 parts, Radix Angelicae Sinensis 6 parts and 5 parts of Radix Glycyrrhizae.
5. according to the Chinese medicine composition of the arbitrary described treatment pulmonary carcinoma of claim 1-4, it is characterised in that described Chinese medicine composition be made into capsule, Tablet, powder or decoction.
6. according to the Chinese medicine composition of the arbitrary described treatment pulmonary carcinoma of claim 1-4, it is characterised in that the preparation method bag of described Chinese medicine composition Include following steps:
Step 1, weigh each taste raw medicinal material in proportion；
Step 2, by Folium Artemisiae Argyi, Rhizoma Corydalis, roundleaf Radix Celastri Orbiculati, Radix Adenophorae (Radix Glehniae), Semen Lepidii (Semen Descurainiae), Herba Duchesneae Indicae, Herba Hemipiliae Flabellatae, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Fructus Schisandrae Chinensis, Herba Houttuyniae, Radix Angelicae Sinensis and Radix Glycyrrhizae decontamination respectively, cleans, dries, be ground into coarse powder；
Step 3, the coarse powder of step 2 gained is mixed, add the purified water of 5-12 times of medical material weight, decoct 2-3 time, each 2-5 hour, mistake Filter, merging filtrate, when being condensed into 55 DEG C-65 DEG C, relative density is the water extracting liquid of 1.15-1.20；
Step 4, toward the water extracting liquid of step 3 gained adds the 50-80% ethanol of 4-8 times of medical material weight, in 5-10 DEG C of cold preservation 20-48 hour, Decompression distillation, removes ethanol, and it is the Chinese medical concrete of 1.15-1.20 that filtrate is concentrated into relative density under 55 DEG C of-65 DEG C of environment；
Step 5, Chinese medical concrete step 4 obtained dry, pulverize, and cross 100-200 mesh sieve, obtain traditional Chinese medicine fine powder, in described traditional Chinese medicine fine powder Add adjuvant and make finished product Chinese medicine preparation.
7. the method for the Chinese medicine composition preparing treatment pulmonary carcinoma as claimed in claim 1, it is characterised in that comprise the following steps:
Step 1, weigh each taste raw medicinal material in proportion；
Step 2, by Folium Artemisiae Argyi, Rhizoma Corydalis, roundleaf Radix Celastri Orbiculati, Radix Adenophorae (Radix Glehniae), Semen Lepidii (Semen Descurainiae), Herba Duchesneae Indicae, Herba Hemipiliae Flabellatae, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Fructus Schisandrae Chinensis, Herba Houttuyniae, Radix Angelicae Sinensis and Radix Glycyrrhizae decontamination respectively, cleans, dries, be ground into coarse powder；
Step 3, the coarse powder of step 2 gained is mixed, add the purified water of 5-12 times of medical material weight, decoct 2-3 time, each 2-5 hour, mistake Filter, merging filtrate, when being condensed into 55 DEG C-65 DEG C, relative density is the water extracting liquid of 1.15-1.20；
Step 4, toward the water extracting liquid of step 3 gained adds the 50-80% ethanol of 4-8 times of medical material weight, in 5-10 DEG C of cold preservation 20-48 hour, Decompression distillation, removes ethanol, and it is the Chinese medical concrete of 1.15-1.20 that filtrate is concentrated into relative density under 55 DEG C of-65 DEG C of environment；
Step 5, Chinese medical concrete step 4 obtained dry, pulverize, and cross 100-200 mesh sieve, obtain traditional Chinese medicine fine powder, in described traditional Chinese medicine fine powder Add adjuvant and make finished product Chinese medicine preparation.
CN201610196388.6A 2016-03-31 2016-03-31 Folium-artemisiae-argyi-containing traditional Chinese medicine composition for treating lung cancer and preparation method thereof Withdrawn CN105748929A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610196388.6A CN105748929A (en) 2016-03-31 2016-03-31 Folium-artemisiae-argyi-containing traditional Chinese medicine composition for treating lung cancer and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610196388.6A CN105748929A (en) 2016-03-31 2016-03-31 Folium-artemisiae-argyi-containing traditional Chinese medicine composition for treating lung cancer and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105748929A true CN105748929A (en) 2016-07-13

Family

ID=56346852

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610196388.6A Withdrawn CN105748929A (en) 2016-03-31 2016-03-31 Folium-artemisiae-argyi-containing traditional Chinese medicine composition for treating lung cancer and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105748929A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103127433A (en) * 2013-03-08 2013-06-05 陈印安 Chinese medicament for treating lung cancer and preparation method thereof
CN103550696A (en) * 2013-11-01 2014-02-05 田静 Medicine for treating lung cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103127433A (en) * 2013-03-08 2013-06-05 陈印安 Chinese medicament for treating lung cancer and preparation method thereof
CN103550696A (en) * 2013-11-01 2014-02-05 田静 Medicine for treating lung cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘永新: "《国家药典中药实用手册》", 30 April 2011, 中医古籍出版社 *

Similar Documents

Publication Publication Date Title
CN104984297A (en) Application of pharmaceutical composition in preparation of drugs for treating amenorrhea
CN103316192B (en) Traditional Chinese medicine foot-bathing liquid for treating lumbocrural pain and preparation method thereof
CN113730535A (en) Traditional Chinese medicine composition for treating lung cancer and preparation method and application of traditional Chinese medicine preparation of traditional Chinese medicine composition
CN103550506A (en) Traditional Chinese medicine composition cooperatively used in radiotherapy
CN103341013B (en) A kind of Chinese medicine for the treatment of lumbago and skelalgia
CN104873926A (en) Traditional Chinese medicine preparation for treating diarrhea as well as preparation method and application of traditional Chinese medicine preparation
CN105521246A (en) Medicinal preparation for treating lung cancer and applications of medicinal preparation
CN105770673A (en) Application of Chinese herba preparation containing folium artemisiae argyi in preparing drug for treating chronic gastritis
CN105748929A (en) Folium-artemisiae-argyi-containing traditional Chinese medicine composition for treating lung cancer and preparation method thereof
CN104189770A (en) Pharmaceutical composition for treating tuberculous pleuritis and preparation method thereof
CN112691168B (en) Traditional Chinese medicine composition for preventing and treating nuclear radiation injury and preparation method thereof
CN104258037A (en) Traditional Chinese medicine composition for treating lung cancer and preparation method thereof
CN114588240B (en) Traditional Chinese medicine composition for treating colorectal cancer and preparation method and application thereof
CN107243071B (en) Traditional Chinese medicine preparation for assisting lung cancer chemotherapy and preparation method thereof
CN106620632A (en) Drug capsules for preventing and treating chronic atrophic gastritis
CN105412673A (en) Drug for treating Hashimoto disease and preparing method thereof
CN104784547A (en) Traditional Chinese medicine composition having synergistic effect on radiotherapy and preparation method
CN104758749A (en) Traditional Chinese medicine composition for treating liver cancer
CN113116987A (en) A Chinese medicinal composition for treating tumor, and its preparation method
CN104645302A (en) Medicine for alleviating postoperative chemotherapy-induced nausea and vomiting of patient with encephaloma and preparation method
CN104547862A (en) Use of traditional Chinese medicine preparation in preparation of medicine for treating bone fracture
CN104225004A (en) Auxiliary anti-tumor traditional Chinese medicine preparation containing Brazilian ginseng
CN103877313A (en) Chinese herbal medicine for rising leukocyte platelets after radiotherapy and preparation method thereof
CN105521150A (en) Preparation method traditional Chinese medicine for reducing blood fat
CN114533695A (en) An oral Chinese medicinal composition for treating ankylosing spondylitis and its preparation method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160713